Azitra, Inc. (AZTR)

0.1790 -0.0090 (-4.79%) As of 10:22AM EDT. Market open.

Azitra, Inc.

21 Business Park Drive
Branford, CT 06405
United States
(203) 646-6446
https://azitrainc.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 10

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Francisco D. Salva	President, CEO & Director	427.03k	N/A	1971
Mr. Travis M. Whitfill M.P.H., Ph.D.	Co-Founder, COO & Director	161.61k	N/A	1990
Mr. Norman Staskey	CFO, Treasurer & Secretary	314.02k	N/A	1970

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.

Corporate governance

Azitra, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.